T1	Participants 113 135	operable breast cancer
T2	Participants 405 430	metastatic breast cancer.
T3	Participants 545 567	operable breast cancer
T4	Participants 590 737	Women with invasive breast cancer were eligible if there were one to three positive lymph nodes or if the node-negative tumor was greater than 1 cm
T5	Participants 739 784	Patients were randomly assigned after surgery
T6	Participants 967 1053	patients with estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumors
T7	Participants 1074 1106	2,882 eligible patients enrolled
